INKT

MiNK Therapeutics, Inc.

1.00 USD

Last updated Dec 3, 01:37 UTC

Yesterday HIGH

$1.09

Yesterday LOW

$1.02

52w HIGH

$3.34

52w LOW

$0.85

EPS

-0.15

PE

-6.67

Next Earnings

Mar 19, 2024

Overview News Government Trades

MiNK Therapeutics, Inc. stock is down -14.55% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.

MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

minktherapeutics.com

richadhand@benzinga.com

Wed Apr 19, 2023

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $7 price target.
Happy Mohamed

Tue Apr 18, 2023

MiNK Therapeutics Announces Clinical Data Of Allogeneic iNKT Cells In Solid Tumor Cancers At The AACR Annual Meeting

Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers. In a patient with metastatic gastric cancer who had no response
Happy Mohamed

Thu Mar 30, 2023

Agenus Announces Dividend Of 5M Shares Of Its Subsidiary, MiNK Therapeutics, To Shareholders Of Agenus As Of April 17, 2023

Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million
Benzinga Newsdesk

Wed Mar 22, 2023

Evercore ISI Group Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $3

Evercore ISI Group analyst Maneka Mirchandaney maintains MiNK Therapeutics (NASDAQ:INKT) with a Outperform and lowers the price target from $4 to $3.
richadhand@benzinga.com

Wed Mar 22, 2023

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $7 price target.
Benzinga Newsdesk

Tue Mar 21, 2023

MiNK Therapeutics Q4 EPS $(0.23) Misses $(0.21) Estimate; Cash Balance Of $19.6M

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 27.78 percent decrease over losses of $(0.18) per share
Benzinga Insights

Tue Mar 21, 2023

Earnings Scheduled For March 21, 2023

Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Benzinga Insights

Mon Mar 20, 2023

Preview: MiNK Therapeutics's Earnings
Benzinga Insights

Fri Mar 17, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Happy Mohamed

Wed Mar 15, 2023

MiNK Therapeutics To Present Updated Clinical Data Of allo-iNKT Cell Therapy In Solid Tumors At AACR Annual Meeting On Tuesday April 18, 2023

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a